Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Ergomed PLC    ERGO   GB00BN7ZCY67

ERGOMED PLC (ERGO)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 11:35:21 am
172.5 GBp   -1.43%
2018ERGOMED PLC : annual earnings release
2017ERGOMED PLC : half-yearly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
175(c) 175(c) 175(c) 175(c) 172.5(c) Last
6 433 0 1 041 317 51 135 33 763 Volume
0.00% 0.00% 0.00% 0.00% -1.43% Change
More quotes
Financials (GBP)
Sales 2018 51,7 M
EBIT 2018 -1,13 M
Net income 2018 -1,00 M
Finance 2018 7,00 M
Yield 2018 -
Sales 2019 59,8 M
EBIT 2019 1,80 M
Net income 2019 3,00 M
Finance 2019 9,55 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 1,37x
EV / Sales2019 1,14x
Capitalization 77,7 M
More Financials
Company
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring... 
More about the company
Surperformance© ratings of Ergomed PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on ERGOMED PLC
01/17ERGOMED : Congratulates Octapharma on Gaining Marketing Authorisation for Fibryg..
AQ
01/04ERGOMED : Directors' Dealing
PU
2018ERGOMED : issue of shares
PU
2018ERGOMED : Unaudited Interim Results for the six months ended 30 June 2018
AQ
2018ERGOMED : Interim Results
PU
2018ERGOMED : Notice of Interim Results
PU
2018Asarina Pharma AB publishes prospectus in connection with share issue of SEK ..
AQ
2018ERGOMED : Change of auditor
PU
2018ERGOMED : strengthens Management Team and Board with appointment of Stuart Jacks..
AQ
2018ERGOMED : Trading update
AQ
More news
Analyst Recommendations on ERGOMED PLC
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ERGOMED PLC
Duration : Period :
Ergomed PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERGOMED PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,65  GBP
Spread / Average Target 53%
Managers
NameTitle
Stephen A. Stamp Chief Executive Officer & Director
Peter Lutz George Chairman
Jan Petracek Chief Operating Officer & Executive Director
Stuart Robert Jackson Chief Financial Officer & Director
Miroslav Reljanovic Executive Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ERGOMED PLC9.87%100
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300